Russell Frank Company’s Catalyst Pharmaceutical CPRX Stock Holding History

Russell Frank Company’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-135,329	Closed	-$406K	–	2990
2015 Q3	$406K	Sell	135,329 -66,473	-33%	-$287K	﹤0.01%	2533
2015 Q2	$833K	Hold	201,802	–	–	﹤0.01%	2396
2015 Q1	$874K	Buy	+201,802	New	+$727K	﹤0.01%	2211

Other funds holding CPRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Frank Company's CPRX Position: Q4 2015 in Review

Russell Frank Company sold out of Catalyst Pharmaceutical (CPRX) in Q4 2015, closing a stake of 135,329 shares — an estimated $406K sold.

Russell Frank Company first reported a position in CPRX in Q1 2015 and held it in 3 quarters. The position peaked at $874K in Q1 2015. 85 funds tracked by Wall St. Rank hold CPRX as of Q4 2015.

Russell Frank Company reported no remaining Catalyst Pharmaceutical position as of Q4 2015 after selling out during the quarter.
Russell Frank Company sold 135,329 Catalyst Pharmaceutical shares in Q4 2015, an estimated $406K.
Russell Frank Company first reported a position in Catalyst Pharmaceutical in Q1 2015 and held it in 3 quarters.
Russell Frank Company's Catalyst Pharmaceutical position peaked at $874K in Q1 2015.
85 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2015.

Based on Russell Frank Company's 13F filing for Q4 2015, filed 27 Jan 2016.